Conditional deletion of Men1 in the pancreatic β-cell leads to glucagon-expressing tumor development

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• The tumor suppressor menin (Men1) is crucial for regulating pancreatic beta-cell proliferation.
• Understanding the molecular mechanisms driving pancreatic islet tumorigenesis is essential for developing targeted therapies.

Purpose of the Study:

• To investigate the role of menin in pancreatic beta-cell proliferation and tumorigenesis.
• To elucidate the molecular changes, including transcription factor alterations, following menin ablation in beta cells.

Main Methods:

• Utilized a mouse model with floxed Men1 alleles selectively ablated in beta cells using Cre-recombinase under the insulin promoter (RipCre).
• Analyzed tumor development, including glucagon-expressing tumors and insulinomas, in mutant mice.
• Assessed the expression of key transcription factors, such as Brn4 and MafB, in tumor cells and examined beta-cell specific transcription factors in mutant beta cells.

Main Results:

• Menin deficiency in pancreatic beta cells, despite the use of a beta-cell specific Cre-recombinase, led to the development of both glucagon-expressing tumors and insulinomas.
• The glucagon-expressing tumor cells exhibited menin deficiency and expressed mature alpha-cell transcription factors, Brn4 and MafB.
• Inactivation of beta-cell specific transcription factors was observed in the menin-deficient beta cells.

Conclusions:

• Menin ablation in pancreatic beta cells disrupts normal cell function and promotes tumorigenesis.
• The loss of menin leads to the inactivation of critical transcription factors, driving the development of glucagon-expressing tumors.
• This research provides novel insights into the pathogenesis of pancreatic islet tumors.